Tuesday brings the expiry of the first patent on the pain treatment OxyContin, and the FDA has yet to decide whether to allow generic-drug makers to manufacture the drug's original formulation or to wait until newer abuse-resistant versions' patient protection ends in several years. "We are working to take action, as soon as the science and law allow us to do so," the said Deputy Director Douglas D. Throckmorton of the FDA's Center for Drug Evaluation and Research.

Related Summaries